Clinical Trial: A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937411) titled 'A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants' on April 15.

Brief Summary: The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants.

Participation could last up to 7 weeks

Study Start Date: Feb. 13, 2023

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: LY4100511

Administered orally

Recruitment Status: COMPLETED

Sponsor: Eli Lilly and Company

Published by HT Digital Content Services with permission from Health Daily Digest....